Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

t. With continued pegloticase therapy beyond 6

months in the GOUT 3 study, the proportion of patients demonstrating a

Complete Response for tophus resolution increased over time in both the

every 2 weeks and every 4 weeks groups. While other clinical

assessments also showed clinical improvements, such as a partial tophus

response, it is only the tophus Complete Response that was pre-

specified as a clinical criterion by which to measure success. It is

very encouraging that many patients, who had a tophus partial response

in the first six months of treatment, developed a Complete Response

over a longer treatment period in GOUT 3.

-- Gout Flares: The GOUT 1 and GOUT 2 pivotal studies assessed the affect

of pegloticase treatment on both an efficacy and safety secondary

endpoints in gout flares. As with all urate-lowering therapies, the

frequency of flares increased upon initiation of pegloticase treatment

as expected. The treatment-failure gout patients in the Phase 3

program had a high frequency of gout flares prior to study entry, as

shown by the approximately 1.7 flares per the initial 3-month period

for the placebo group. In the pooled analyses, pegloticase-induced

increase in gout flares occurred in both treatment groups during Months

1-3 to a frequency of about 2.3 and 2.7 respectively, whereas the

placebo group showed no change in flare frequency during the same 3-

month period.

New data presented at ACR demonstrates that in Months 4-6 patients

administered pegloticase every 2 weeks had a statistically

significant lower flare incidence and frequency compared to placebo

patients in the pooled analysis. Additionally, in Months 4-6, the

pegloticase every 4 weeks group had a frequency of gout flares similar

to placebo indi
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... PALO ALTO, Calif., Oct. 24 Vivo Ventures, a ... that,James Huang will join the firm as an Executive ... Mr. Huang will,work with Vivo,s portfolio companies while enhancing ... James coming on board and what he will be ...
... 24 Cell Therapeutics,Inc. (CTI) (Nasdaq and ... 19th annual AACR-NCI-EORTC Symposium show its bis-platinate ... to currently,marketed platinum agents carboplatin, cisplatin and ... in late 2008. "Bis-platinates represent a ...
... is available in German . , Hydrogen fuel ... have so far suffered from being insufficiently competitive. At the ... Strasser has now developed a new class of electrocatalyst that ... active phase of the catalyst consists of nanoparticles with a ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Platinum-rich shell, platinum-poor core 2
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... cold is not only uncomfortable, it can be deadlycausing ... years now, scientists have understood the molecular mechanisms that ... high temperatures that directly trigger heat sensor proteins known ... is how animals sense very small temperature differences in ...
... Detecting deadly fumes in subways, toxic gases ... is becoming easier and more efficient with a ... improve the technique,s sensitivity, scientists must design better ... them. , Researchers at the University of Illinois, ...
... mothers need to rebuild muscles and strengthen their stamina. Now ... that recovery during a pilot study at Case Western Reserve ... in bed is not a benign kind of thing," says ... She has been studying the effects of bed rest ...
Cached Biology News:Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3Killer pulses help characterize special surfaces 2Ante-partum bed rest moms get active in Case Western Reserve University study 2
Phospho-Btk (Tyr223) Antibody...
Rad51B...
p27 rabbit polyclonal antibody...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
Biology Products: